$RMS.PA

Hermes stock target lowered at Citi on continued China weakness

Citi lowered its price target on Hermes (HRMS) to €1,540 from €1,689, citing weak demand in China and France. The bank reduced growth forecasts for leather and non-leather goods, and cut 2026-2028 sales, operating profit, and EPS estimates by about 1%. Hermes grew 6.1% in the first half of 2023.

Original reporting
Published Sep 30, 2026, 4:47 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 4:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$RMS.PA
Bearish
high confidence
Mentioned
$RMS.PA
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RMS.PABearishMed
01

Why it matters

The downgrade reflects a cautious stance on luxury demand, potentially prompting short‑term sell pressure.

02

Market read

Analyst target reduction is a fresh catalyst that may move Hermes stock and influence the broader luxury sector.

03

What to watch

Strong performance in leather goods and stable margins could cushion the impact.

Relevance 7/10Novelty 6/10Timing: today

Background

Citi's note adjusts Hermes' forecasts for Q3‑Q4 2026 and trims growth assumptions for leather and non‑leather categories.

Company-level read

Ticker impact

$RMS.PABearishHigh confidence
Context

Citi lowered Hermes' price target to €1,540 citing continued demand weakness in China and a softer French backdrop.

Expected impact

likely pressure as the market prices in the reduced target

Evidence & confidence

Target cut reflects weaker demand outlook, which typically translates into lower share price.

Market effects

Luxury sector may face broader scrutiny as China demand softens.

European luxury stocks could see modest pullback.

Signals potential slowdown in high‑end consumer spending in Asia.

Counterpoint

If Hermes can diversify beyond China, the target cut may be overblown.

Key entities

  • Citi

    Equity research house issuing the target cut.

  • Hermes

    French luxury goods group.

Related articles

$RMS.PAMed

Hermes Q3 sales rise 5.5% on leather goods and Americas strength

Hermes reported a 5.5% rise in Q3 revenue to €4.096 billion, driven by leather goods and strong sales in the Americas, Europe, and Japan. Nine-month revenue increased 2.9% to €12.26 billion, with currency swings reducing sales by €310 million. The company confirmed its medium-term growth goals despite economic uncertainties and will publish full-year results on February 12, 2027, according to the company.

$MC.PAMed

Luxury stocks slide after LVMH’s weak fashion sales spark recovery doubts

LVMH reported weaker-than-expected sales in fashion and leather goods, with a 5% decline, missing estimates. Chinese demand for Louis Vuitton weakened, raising concerns about sector recovery. Shares of LVMH, Hermes, Kering, Moncler, Dior, and Richemont fell. Group revenue was €18.5 billion, below expectations. Growth in watches and jewelry slowed to 6%. LVMH's market value has dropped roughly 40% this year.

$SHOPMed

Oppenheimer sees web, commerce software Q3 backdrop improving, AI worries linger

Oppenheimer notes improved interest in web and e-commerce software ahead of Q3 results, but AI concerns remain. Shopify (SHOP) is expected to exceed revenue forecasts with strong consumer demand. Wix.com (WIX) may see slower growth due to AI shifts. GoDaddy (GDDY) is on track with forecasts, and Commerce.com (CMCM) expects revenue in line with estimates. Oppenheimer raised Shopify's price target to $205.

$RAPPMedAI 9/10

Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial

Rapport Therapeutics (NASDAQ: RAPP) announced positive Phase II trial results for RAP-219 in bipolar mania, with plans to advance to Phase III. The drug was well-tolerated, with mild to moderate adverse events. The company aims to meet with the FDA in Q1 2027 and start Phase III trials in the second half of 2027. Rapport also expects to report long-term safety data for RAP-219 in focal onset seizures in Q4 2026.